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by the year 2020, primarily because of external demands and internal 
investments.  
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OBJECTIVES: Health technology assessment bodies are increasingly reviewing 
the clinical and economic evidence on various surgical procedures. Such reviews 
typically use a hierarchy of evidence, with randomized controlled trials (RCTs) 
designated Level I evidence and case-control and case-series studies designated 
Levels III and IV. The objective of this study was to explore the evidence 
available to determine the value of a well-established surgical procedure. 
METHODS: A structured search of PubMed was conducted on rotator cuff surgery 
using Medical Subject Heading search terms. Internet searches identified 
evidence-based guidelines for this condition. RESULTS: Two RCTs evaluating the 
efficacy of arthroscopic repair of rotator cuff tears concluded that arthroscopic 
repair was superior to the alternatives studied. Ten systematic reviews 
examining studies of surgical technique modifications for rotator cuff surgery 
were identified. All 10 reviews reported that, despite limitations, there was 
enough evidence to identify surgical techniques that resulted in improved 
clinical outcomes. Most of the systematic reviews found Level III or Level IV 
evidence for recommending one type of surgery over another. In 2010, the 
American Academy of Orthopaedic Surgeons (AAOS) published evidence-based 
guidelines to improve treatment for 25 different rotator cuff problems; 74 studies 
were deemed of sufficient quality for use in the guidelines. However, more than 
half of the 25 recommendations (n=15) were characterized as inconclusive owing 
to the levels of evidence available for review. CONCLUSIONS: The 
pharmaceutical framework for evidence hierarchy often may not be appropriate 
for surgical procedures and devices. There are challenges to running clinical 
trials in surgical setting, making them impractical and unaffordable. Especially 
with well-established procedures, evidence review will require a balanced 
approach using the best available evidence and clinical expertise.  
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OBJECTIVES: The Affordable Care Act (ACA) has been upheld by the United 
States Supreme Court. Four principles of the ACA are driving changes in the US 
health care system, those principles are improving outcomes, quality, safety and 
containing costs. This study looks at several product outcomes guarantees to see 
if they support the cited ACA principles to benefit the health care system. 
METHODS: A review and analysis of published payer coverage policies and 
contracts entered into by product manufacturers with several US payers. 
RESULTS: Three publically available examples were analyzed and described 
herein: a) WellPoint analyzed over 55,000 claims for use of zafirlukast, 
montelukast sodium and zileuton and determined that outcomes for these 
products were better and more cost effective even when used first-line, outside 
of FDA indication; b) Cigna entered into an agreement with Merck where 
additional rebates are paid by Merck if patients who are on sitagliptin if patients 
stay on therapy and see blood sugar levels fall; c) EMD Serono and Prime 
Therapeutics have an agreement where rebates are paid if the total cost of care 
of an interferon beta 1a patient is greater than a patient on other MS drugs, or if 
adherence to the drug exceeds a specified level. CONCLUSIONS: Outcomes 
guarantees by product manufacturers are still in their infancy in the United 
States, but recent examples show that payers are looking at these agreements as 
a way to improve outcomes and control costs. The ACA may help to drive more 
outcomes guarantee agreements because they do support the key principles of 
the ACA. Drug manufacturers must clearly understand how their products will 
perform when used outside of a clinical trial in order to negotiate such 
agreements.  
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OBJECTIVES: Our aim was to gather perspectives from a diverse group of payers 
on how the rapidly evolving field of comparative effectiveness research 
(CER)/relative effectiveness (RE) will impact evidentiary standards for pricing and 
coverage decisions by 2020. METHODS: We conducted semi-structured 
interviews with 16 senior officials representing large payers, accountable care 
organizations, HTA groups, and pricing and reimbursement bodies in the US and 
Europe. An online survey was used to assess current use of CER/RE evidence and 
potential trends that might influence its use for decision making by 2020. The 
interview was designed to elicit their definitions of CER/RE and structured 
around 4 hypothetical cases resembling therapeutics expected to be more 
common and poised to create policy challenges by 2020. Topics included 
acceptance of designs (e.g., pragmatic trials) and analytic methods associated 
with CER/RE (e.g., indirect comparisons). A systematic content review was used 
to extract relevant information. RESULTS: While there was marked diversity in 
responses, there were some common themes. Respondents anticipate growing 
reliance on policy levers such as conditional reimbursement and prior 
authorization to control diffusion. Randomization will remain an essential 
component to assess comparative effectiveness. Respondents anticipate more 
aggressively using techniques like cluster randomization to conduct studies in 
their population. Case studies provided important insights into situations when 
certain types of CER evidence may be acceptable (e.g., observational data when 
differences between drugs are largely convenience). Payers would like to see but 
remain skeptical about harmonized approaches such as adaptive licensing to 
stage evidence development. CONCLUSIONS: Industry perceptions that CER will 
change payers' evidentiary requirements in the future are consistent with our 
findings. This arises both from a growing investment in analyses of their own 
data and increased reliance on policy tools to control diffusion that will drive the 
type of evidence industry will be required to produce.  
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OBJECTIVES: In the development and post-launch support of medicines, there 
are a myriad of issues in selecting comparator(s) for trials, studies, modeling 
and/or other analyses. The principles and process for the selection of 
comparators has a limited body of literature focused mainly on the randomized 
control trial design. Guidance documents exist but are not always sufficiently 
clear or consistent in their criteria. Our objective is to examine the complexities 
in making a generalizable comparator selection considering the many issues and 
questions found in the literature. METHODS: We conducted a comprehensive 
search of the published and grey literature, guidelines from regulatory, HTA, and 
professional organizations that addressed the comparator selection process as 
well as case studies and published opinion on the issue. We excluded 
publications that did not address issues, principles, and criteria for selecting 
comparators. We independently assessed this review with the final framework 
developed by team consensus. RESULTS: We propose a framework organizing 
the principles, methods and unresolved issues for the appropriate selection of a 
comparator product. It consists of: 1) foundational elements (e.g., clinical 
equipoise, ethical issues); 2) gaps in existing knowledge (e.g., systematic 
evidence reviews, is there a clear standard of care?); 3) hypotheses/questions to 
be addressed (e.g., intended purpose of the study/analysis, known characteristics 
of the investigational product); 4) study or analyses design-specific comparator 
criteria; and 5) exploration and validation of the proposed choice(s). 
CONCLUSIONS: Currently, several efforts are underway to define a clear and 
equitable process for comparator selection that is more consistent and 
acceptable to decision-makers and stakeholders. Our proposed framework could 
help support development of a more transparent and harmonized comparator 
selection process that better addresses the evidence needs of industry, 
regulators, HTA agencies and payers.  
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OBJECTIVES: To understand hospitalization costs, expenses covered by 
insurance and disease distribution among urban inpatients with basic health 
insurance (BHI) in China between 2009 and 2010, providing data evidence for the 
government further improving BHI policies and drug regulation system. 
METHODS: A nationwide, cross-sectional sampling of urban inpatients with BHI 
was conducted in mainland China. A retrospective analysis was adopted and all 
results were extrapolated to the whole country according to the population, 
economics and other factors in the inpatients’ cities. The statistics analysis 
software was SQL Server 2003. RESULTS: There were 31,460,000 cases after 
extrapolated (sample=236,366) in 2010, with an increase of 13.92% than that of 
the previous year. Second-class hospitals received more hospitalization cases 
(45.47% of the total ) in 2010 than the previous year (41.28% of the total). Average 
hospitalization cost per visit in 2010 was 8056 RMB, an increase of 5.05% from the 
previous year. Remarkably, medication expenses accounted for about 49%, which 
was approximately equal to the previous year. The expenses covered by BHI 
accounted for 67.73% for each vist, which was higher than that of the previous 
year. Cerebrovascular disease had the most hospitalization cases (9.95% of the 
total), followed by cancer, ischemic heart disease, Hypertension and chronic 
lower respiratory diseases. The total hospitalization cost of cancer (36.403 billion 
RMB) was the highest, followed by cerebrovascular disease (25.242 billion RMB) 
and ischemic heart disease (20.472 billion RMB). CONCLUSIONS: The average 
hospitalization costs per visit and total hospitalization costs all increased. And 
rational drug use should be still paid more attention since the drug costs 
percentage was steadily high. Helping inpatients select proper hospitals to see 
doctors and strengthening the administration of diseases cost highly will be 
helpful for reducing the medical costs.  
 
PHP23  
THE 2012 PRICE TREND ANALYSIS FOR 12 LEADING THERAPY AREAS IN 12 
SELECTED DEVELOPED ADN EMERGING MARKETS  
Marinoni G, Lockwood C, Mehta P, Ando G 
IHS, London, UK  
